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Population-Based Cohort Study
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OBJECTIVES: The association between aspirin use and improved survival after colorectal cancer diagnosis may be more
pronounced in tumors that have PIK3CAmutations or high PTGS2 expression. However, the evidence of a difference in association
by biomarker status lacks consistency. In this population-based colon cancer cohort study the interaction between these
biomarkers, aspirin use, and survival was assessed.
METHODS: The cohort consisted of 740 stage II and III colon cancer patients diagnosed between 2004 and 2008. Aspirin use was
determined through clinical note review. Tissue blocks were retrieved to determine immunohistochemical assessment of PTGS2
expression and the presence of PIK3CAmutations. Cox proportional hazards models were used to calculate hazard ratios (HR) and
95% confidence intervals (CI) for colorectal cancer-specific and overall survival.
RESULTS: In this cohort aspirin use was associated with a 31% improvement in cancer-specific survival compared to non-use
(adjusted HR= 0.69, 95% CI 0.47–0.98). This effect was more pronounced in tumors with high PTGS2 expression (PTGS2-high
adjusted HR= 0.55, 95% CI 0.32–0.96) compared to those with low PTGS2 expression (PTGS2-low adjusted HR= 1.19, 95% CI
0.68–2.07, P for interaction= 0.09). The aspirin by PTGS2 interaction was significant for overall survival (PTGS2-high adjusted
HR= 0.64, 95% CI 0.42–0.98 vs. PTGS2-low adjusted HR= 1.28, 95% CI 0.80–2.03, P for interaction= 0.04). However, no interaction
was observed between aspirin use and PIK3CA mutation status for colorectal cancer-specific or overall survival.
CONCLUSIONS: Aspirin use was associated with improved survival outcomes in this population-based cohort of colon cancer
patients. This association differed according to PTGS2 expression but not PIK3CA mutation status. Limiting adjuvant aspirin trials
to PIK3CA-mutant colorectal cancer may be too restrictive.
Clinical and Translational Gastroenterology (2017) 8, e91; doi:10.1038/ctg.2017.18; published online 27 April 2017
Subject Category: Colon/Small Bowel
INTRODUCTION
Observational studies and long-term follow-up of randomized
trials assessing aspirin use in cardiovascular disease indicate
that regular aspirin use is associated with a reduced risk of
colorectal neoplasia.1 Further long-term follow-up of these
trials suggests aspirin use is associated with a reduction in
both the incidence and subsequent development of metastatic
disease.2 Similarly, a recent population-based cohort study
with over 23,000 colorectal cancer patients demonstrated that
post-diagnostic aspirin use was associated with improved
cancer-specific survival.3 Pre-clinical evidence confirms the
biological plausibility of these associations and suggests
aspirin may have pleiotropic anti-cancer effects.4 Although the
exact mechanisms remain unclear they are likely to
involve prostaglandin-endoperoxide synthase 2 (PTGS2, also
known as cyclooxygenase-2 or COX-2) dependent and
independent pathways.4,5 Taken together, this data suggests
aspirin could have utility in the adjuvant treatment of colorectal
cancer.
A number of clinical trials assessing the role of adjuvant
aspirin therapy (low- and high-dose) in colorectal cancer have
recently started recruitment (NCT00565708, NCT02607072,
NCT02301286, ISRCTN74358648). However, the potential
side effects associated with aspirin use, including major
gastrointestinal bleeding, and the understanding that color-
ectal cancers are heterogeneous has led to attempts to better
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identify those patients who may derive a survival benefit.6,7
Allowing for tumor heterogeneity, molecular pathological
epidemiology studies can facilitate assessment of the
interaction between molecular biomarkers and lifestyle
or other exogenous factors and the subsequent effect on
cancer survival.5,8 As a result, they can provide mechanistic
insight into the anti-cancer effect of the exposure being
assessed and contribute to the development of precision
medicine.5
PTGS2 is the rate limiting enzyme in the conversion of
arachidonic acid to prostaglandins.9 Prostaglandins have the
potential to enhance the neoplastic process by inhibiting
apoptosis, stimulating proliferation and promoting
angiogenesis.4 Phosphatidylinositol 3-kinase (PI3K) signaling
pathways also play an important role in colorectal cancer
carcinogenesis.6 Phosphatidylinositol-4,5-biphosphonate
3-kinase (PIK3CA) encodes the p110α catalytic subunit of
PI3K and mutations in this gene constitutively activate the
PI3K pathway.7,10 Subsequent downstream activation of
protein kinase B (AKT) results in PTGS2 upregulation and
the potential to inhibit apoptosis.11,12 Overexpression of
PTGS2 and the presence of PIK3CA mutations have been
shown to differentiate the survival benefit associated with
aspirin use in some6,7,9 but not all7,13,14 colorectal cancer
observational studies. As the evidence of a difference in
association by biomarker status lacks consistency further
validation is required.
Therefore, the aim of this studywas to assess the interaction
between aspirin use, the biomarkers PTGS2 and PIK3CA, and
survival in a population-based cohort study of patients with
stage II and III colon cancer.
METHODS
Study cohort. All stage II and III colon cancer patients
(International Classification of Disease code C18) diagnosed
in Northern Ireland between 2004 and 2008 were identified
from the Northern Ireland Cancer Registry (n=1,862). Rectal
cancers were excluded from this molecular pathological
epidemiology study due to the potential for neoadjuvant
radiotherapy to alter tumor expression profiles. Following
review of pathology reports the cohort was restricted to
patients with a single primary colon adenocarcinoma who
had undergone a surgical resection (n=1,539). A further 113
patients were excluded after clinical note review for reasons
listed in Figure 1. To facilitate formalin fixed, paraffin-
embedded (FFPE) tissue block retrieval the final cohort was
restricted to patients from two of the five Northern Ireland
Health and Social Care trusts within the remit of the Northern
Ireland Biobank (740 of 1,426, 51.9%). These patients were
representative of the overall Northern Ireland cohort in terms
of age, sex, tumor stage, adjuvant chemotherapy use and
proportion of deaths that occurred (see Supplementary
Table S1 online).
Clinicopathological variables and follow-up. Clinical vari-
ables including adjuvant chemotherapy use, prescription
medication use, family history of colorectal cancer and
Eastern Cooperative Oncology Group (ECOG) performance
status were retrieved from the Northern Ireland Clinical
Oncology Information System (COIS), a prospective electro-
nic record of cancer patient management. This process was
supplemented by a manual chart review when insufficient
information was recorded on COIS or when patients were not
referred to an oncologist for consideration of adjuvant
therapy. Stage and grade of differentiation were extracted
from pathology reports. All patients were followed up for
occurrence and cause of death via linkage to the Northern
Ireland Registrar General’s Office up to 31st December 2013.
Colorectal cancer-specific deaths were defined as those with
an underlying cause of death International Classification of
Disease code C18, C19, C20 (anus) and/or C26 (other and
ill-defined digestive organs).
Assessment of aspirin use. Prescription aspirin use (user
vs. non-user) was assessed early in the post-operative period
for all patients. When medication information was available
on COIS this time point was the initial post-operative
oncology review where current regularly prescribed medica-
tion use is recorded. When medication information was not
available on COIS aspirin exposure was determined from the
post-operative hospital discharge letter. Information on
medication dosage was not consistently recorded on COIS.
Our research group has previously demonstrated that 98.5%
of aspirin prescriptions after colorectal cancer diagnosis in
the UK are for low-dose (75 mg) aspirin.15 Exposure in this
study is therefore considered representative of low-dose
aspirin.
Tumor molecular analysis
FFPE block retrieval and tissue microarray construction. The
Northern Ireland Biobank retrieved slides from all of the
resection specimen blocks for each case. These original
hematoxylin and eosin-stained slides were reviewed by an
expert gastrointestinal histopathologist to select the two most
representative FFPE tumor-rich blocks. Following block
retrieval, a new section was cut for hematoxylin and eosin
staining and the slides were annotated for tissue microarray
(TMA) construction. Blocks were retrieved for 89.3% of the
cohort (661 out of 740). Three representative areas within the
donor blocks of each case were annotated for targeted
coring. Three 1.0mm diameter tissue cores were then
extracted from donor blocks and inserted into recipient blocks
using a manual tissue arrayer (Estigen, Tartu, Estonia) as
described previously.16,17
PTGS2 immunohistochemistry, scoring and assessment. All
immunohistochemistry was performed in the Northern Ireland
Molecular Pathology Laboratory, a research laboratory which
has UK Clinical Pathology Accreditation. In brief, all
immunohistochemistry was performed on the fully automated
Ventana BenchMark XT platform using an OptiView antibody
detection system (Ventana Medical Systems Inc., Tucson,
USA) and a Cell Marque ready to use rabbit monoclonal
antibody to PTGS2 (Ventana, catalog number 760-4254).
QuPath (Queen’s University Belfast, Northern Ireland) image
analysis software facilitated digital immunoscoring. More
detailed information is provided in the Supplementary
Methods (online). A H-score was calculated based on the
extent and intensity of cytoplasmic staining (3 ×% of
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strongly staining cytoplasm+2×% of moderately staining
cytoplasm+1×% of weakly staining cytoplasm, giving a
range of 0–300).18
Independently, an expert gastrointestinal histopathologist
assessed PTGS2 expression in a random 10% sample (207 of
the triplicate TMA cores) using the standardized grading
system (absent, weak, moderate or strong immunostaining)
described by Chan et al.9 Tumors with low PTGS2 expression
(PTGS2-low) were categorized as those demonstrating weak
or absent immunostaining while PTGS2-high tumors had
moderate or strong levels of immunostaining. Receiver-
operating characteristic analysis was subsequently used to
determine the optimal H-score cutoff point that predicted
PTGS2 grading with maximal sensitivity and specificity
(according to Youden’s J statistic using Cutoff Finder19). Using
this methodology, a H-score of 145.5 differentiated PTGS2-
low from PTGS2-high tumors with good interobserver agree-
ment between the digital H-score and the histopathologist’s
grading (agreement 86.5%, κ= 0.70). In the final data set,
PTGS2 expression grading was determined using the median
H-score from the three cores available for each case. Values
above and below 145.5 were considered PTGS2-high and
PTGS2-low respectively. Representative images are shown in
Figure 2.
DNA extraction. Tumor-rich areas of the representative
blocks from each case were annotated for macrodissection.
DNA was extracted according to the manufacturer’s instruc-
tions from five 5 μm sections using the Maxwell 16 Instrument
(Promega, Southampton, UK) and Promega DNA extraction
kit. Quantification of DNA was performed by an absorbance
method using the NanoDrop 2000c spectrophotometer
(Thermo Scientific, Wilmington, USA).
PIK3CA mutation and microsatellite instability status. Mass
spectrometry incorporating the pre-validated ColoCarta
Panel (Agena Bioscience, Hamburg, Germany) was used to
detect the presence of PIK3CA mutations. Samples were
processed at the Genomics Core Technology Unit (Queen’s
University Belfast, Northern Ireland) and the Assays by
Agena Custom Services Laboratory (Hamburg, Germany)
using previously described methods.20 Detection of somatic
mutations at a frequency of 410% for any of eight alleles
(C420R, E542K, E545K, H701P, H1047R, H1047L, Q546K,
or R88Q) was considered evidence of a mutation in the
PIK3CA gene. A failed reaction at a single position resulted in
missing data for PIK3CA status only if the reactions at other
positions were wild-type.21 This panel includes assays that
capture 79% of known PIK3CA mutations including the ‘hot
spot’ mutations in exons 9 and 20 (Q546K, E545K, E542K,
H1047R, and H1047L), which confer constitutive kinase
activity.10
Microsatellite instability (MSI) analysis was performed
within the Northern Ireland Molecular Pathology Laboratory
according to manufacturer’s instructions using the MSI
Analysis System, version 1.2 kit (Promega, Southampton,
UK) for five mononucleotide repeat markers (BAT-25, BAT-26,
NR-21, NR-24 and MONO-27). PCR products were separated
by capillary electrophoresis using an ABI 3500 Genetic
Analyzer (Fisher Scientific—UK Ltd, Loughborough, UK).
The output data were analyzed using GeneMapper v4.1
(Fisher Scientific—UK Ltd, Loughborough, UK) to determine
MSI-high (MSI-H) status (MSI-H vs. non MSI-H).
Statistical analysis. All statistical analysis was performed
using Stata 14 (StataCorp, College Station, TX, USA). The χ2
test was used to compare characteristics between aspirin
Figure 1 Selection of stage II and III colon cancer (adenocarcinoma) patients and samples. NIB, Northern Ireland Biobank.
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users and non-users. The primary outcome of this study was
colorectal cancer-specific survival and the secondary out-
come was overall survival. The association between aspirin
use and survival was assessed in the whole cohort and then
in analyses stratified by biomarker status. Only cases with
information on aspirin exposure (known user vs. known non-
user) were included in the former analysis. Only cases with
available exposure information and tissue for biomarker
assessment were included in the subsequent stratified
analyses. Other missing categorical data were coded as
unknown.
Survival analysis was performed using the Cox proportional
hazards model to calculate hazard ratios (HRs) and asso-
ciated 95% confidence intervals (CI). To control for confound-
ing the cancer-specific survival multivariable model adjusted
for age category at diagnosis (o50/50–o60/60–o70/70–
o80/480), gender, year of diagnosis (continuous variable),
stage (II/III), grade (well or moderate/poor/unknown), MSI
status (MSI-H/non MSI-H/unknown), adjuvant chemotherapy
use within three months of surgery (yes/no), ECOG perfor-
mance status (0–1/2/3–4/unknown) and family history of
colorectal cancer (yes/no/unknown). In addition to the above
variables, the overall survival multivariable model also
adjusted for the Charlson Comorbidity Index score (contin-
uous variable).22 Analyseswere stratified by biomarker status.
Interaction terms for aspirin and PIK3CA or PTGS2 were then
included in the Cox model and the Wald test was used to
assess for statistical interaction. Sensitivity analyses adjusted
for statin use and limited PIK3CA mutations to exons 9 and 20
mutations (confer constitutive kinase activity). Sensitivity
analyses were also conducted based on altering the PTGS2
H-score cutoff point. All P values were two-sided and a value
o0.05 was considered statistically significant.
Ethics. Ethical approval was obtained and tissue was
acquired through the Northern Ireland Biobank (NIB ref.
13–0088) under the remit of the biobank’s ethical approval
from the Office of Research Ethics Committees Northern
Ireland (ORECNI ref. 16/NI/0030).
RESULTS
Patients. Of the 740 patients identified in this population-
based cohort study, information on prescription medication use
Figure 2 PTGS2 immunohistochemistry in colon cancer tissue microarrays (TMAs) and associated mark-up for digital immunoscoring using QuPath image analysis
software. Detected cells are color-coded according to their classification: green, non-tumor; blue, negatively staining tumor; yellow, weakly staining tumor; orange, moderately
staining tumor; red, strongly staining tumor. (a) Original core from a tumor weakly expressing PTGS2 (PTGS2-low). (b) Original core from a tumor strongly expressing PTGS2
(PTGS2-high). (c) QuPath cellular mark-up in the PTGS2-low core (H-score 30.3). (d) QuPath cellular mark-up in the PTGS2-high core (H-score 243.4).
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in the early post-operative period was available for 680
(91.9%). Compared to those with available information on
medication use, patients with no information on medication use
were older and more likely to be diagnosed in the earlier years
Table 1 Clinical and demographic characteristics according to aspirin use
Characteristic Aspirin non-
user (n=534)
No. (%)
Aspirin user
(n= 146)
No. (%)
P value
Age category
o50 43 (8.0) 4 (2.7) 0.003
50–o60 63 (11.8) 8 (5.5)
60–o70 159 (29.9) 38 (26.0)
70–o80 180 (33.7) 59 (40.4)
480 80 (16.7) 37 (25.3)
Gender
Male 286 (53.6) 84 (57.5) 0.39
Female 248 (46.4) 62 (42.5)
Year of diagnosis
2004 79 (14.8) 22 (15.1) 0.35
2005 108 (20.2) 26 (17.8)
2006 110 (20.6) 21 (14.4)
2007 111 (20.8) 35 (24.0)
2008 126 (23.6) 42 (28.8)
Stage
II 313 (58.6) 76 (52.1) 0.16
III 221 (41.4) 70 (48.0)
Grade
Well-moderate 458 (85.8) 119 (81.5) 0.19
Poor 72 (13.5) 27 (18.5)
Unknown 4 (0.8) 0 (0.0)
MSI status
Non MSI-high 337 (63.1) 100 (68.5) 0.29
MSI-high 103 (19.3) 20 (13.7)
Unknown 94 (17.6) 26 (17.8)
Adjuvant chemotherapy
No 346 (64.8) 109 (74.7) 0.03
Yes 188 (35.2) 37 (25.3)
ECOG performance status
0–1 296 (55.4) 76 (52.1) 0.41
2 33 (6.2) 14 (9.6)
3–4 27 (5.1) 5 (3.4)
Unknown 178 (33.3) 51 (34.9)
Family history of colorectal cancer
Yes 289 (54.1) 78 (53.4) 0.44
No 85 (15.9) 18 (12.3)
Unknown 160 (30.0) 50 (34.3)
Comorbidity
Cerebrovascular
disease
26 (4.9) 7 (4.8) 0.97
Chronic pulmonary
disease
55 (10.3) 10 (6.9) 0.21
Congestive heart
failure
22 (4.1) 12 (8.2) 0.04
Diabetes mellitus 54 (10.1) 35 (24.0) o0.001
Myocardial infarction 28 (5.2) 33 (22.6) o0.001
Peptic ulcer disease 22 (4.1) 3 (2.1) 0.24
Peripheral vascular
disease
13 (2.43) 11 (7.5) 0.003
Renal disease 8 (1.5) 5 (3.4) 0.13
ECOG, Eastern Cooperative Oncology Group; MSI, microsatellite instability.
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of the study. However, there was no difference in stage, grade
of tumor differentiation, or MSI status (see Supplementary
Table S2). In patients with known information on medication
use, there were 146 (21.5%) aspirin users. After a mean follow-
up of 5.7 (range 0–10) years there were 299 all-cause and 212
colorectal cancer-specific deaths among these patients.
Aspirin use and survival. Table 1 summarizes the baseline
characteristics between aspirin users and non-users.
Compared to aspirin non-users, aspirin users were older
and less likely to receive adjuvant chemotherapy. As
expected aspirin users also had significantly more cardio-
vascular disease and diabetes. However, tumor grade, stage,
and MSI status were similar between users and non-users.
Aspirin use at the time of diagnosis was associated with a
31% reduction in colorectal cancer-specific mortality
(adjusted HR=0.69, 95% CI 0.47–0.98) compared to non-
use (Table 2). The association between aspirin use and
overall mortality was slightly attenuated (adjusted HR= 0.76,
95% CI 0.57–1.03).
PIK3CA mutations. DNA was extracted in 599 tumor blocks
of the 680 patients in the cohort with information on
medication use at the time of diagnosis. PIK3CA
mutation status (mutant vs. wild type) was available for
98.3% of these samples (589 out of 599). There was no
difference in the proportion of aspirin users in patients with
extracted DNA compared to those without extracted DNA
(21.5 vs. 21.0%). There was a lower proportion of
PIK3CA-mutant tumors in aspirin users (17 out of 129,
13.2%) compared to aspirin non-users (92 of 460, 20.0%)
although the difference was not statistically significant
(P= 0.08).
Compared to wild-type PIK3CA, the presence of a PIK3CA
mutation was not significantly associated with colorectal
cancer-specific survival (adjusted HR= 1.15, 95% CI 0.78–
1.70, Table 2). In stratified analysis there was also no
evidence that the association between aspirin use and
colorectal cancer-specific survival differed by PIK3CA muta-
tion status (mutant PIK3CA adjusted HR=0.66, 95% CI
0.22–2.01 vs. wild-type PIK3CA adjusted HR= 0.69, 95% CI
0.46–1.05, P for interaction 0.80). Similar results were
observed for overall survival (Table 3).
PTGS2 immunohistochemical expression. TMAs were
created from 604 tumor blocks where matched information
on medication use was available. There were similar
proportions of aspirin users in cases with matched TMA
data compared to those without matched TMA data
(21.5 vs. 21.1%). The proportion of PTGS2-high tumors
was 57.7% (75 of 130) among aspirin users and 65.8% (312
of 474) among aspirin non-users (P= 0.09). PTGS2 expres-
sion was not associated with colorectal cancer-specific
survival when PTGS2-high tumors were compared to
PTGS2-low tumors (adjusted HR=0.94, 95% CI 0.69–1.27,
Table 2).
In analyses stratified by PTGS2 expression, aspirin users
had better colorectal cancer-specific survival compared to
Table 3 Aspirin use and colorectal cancer-specific and overall survival stratified by PIK3CA mutation status and PTGS2 immunohistochemical expression
Colorectal cancer-specific survivala P value Overall survivalb P value
Aspirin non-user Aspirin user Aspirin non-user Aspirin user
PIK3CA mutation
No. of deaths/patients 28/92 5/17 46/92 9/17
Unadjusted HR (95% CI) 1 (Reference) 1.03 (0.40–2.67) 0.96 1 (Reference) 1.22 (0.59–2.50) 0.59
Adjusted HR (95% CI) 1 (Reference) 0.66 (0.22–2.01) 0.47 1 (Reference) 0.79 (0.35–1.78) 0.57
PIK3CA wild-type
No. of deaths/patients 120/368 31/112 159/368 50/112
Unadjusted HR (95% CI) 1 (Reference) 0.87 (0.58–1.30) 0.50 1 (Reference) 1.07 (0.78–1.48) 0.67
Adjusted HR (95% CI) 1 (Reference) 0.69 (0.46–1.05) 0.09 1 (Reference) 0.80 (0.57–1.13) 0.20
Aspirin by PIK3CA interaction — — 0.80 — — —
PTGS2-high
No. of deaths/patients 102/312 17/75 146/312 30/75
Unadjusted HR (95% CI) 1 (Reference) 0.66 (0.39–1.12) 0.12 1 (Reference) 0.83 (0.56–1.24) 0.37
Adjusted HR (95% CI) 1 (Reference) 0.55 (0.32–0.96) 0.04 1 (Reference) 0.64 (0.42–0.98) 0.04
PTGS2-low
No. of deaths/patients 50/162 19/55 66/162 29/55
Unadjusted HR (95% CI) 1 (Reference) 1.25 (0.73–2.12) 0.41 1 (Reference) 1.45 (0.94–2.25) 0.09
Adjusted HR (95% CI) 1 (Reference) 1.19 (0.68–2.07) 0.55 1 (Reference) 1.28 (0.80–2.03) 0.30
Aspirin by PTGS2 interaction — — 0.09 — — 0.04
CI, confidence interval; HR, hazard ratio; MSI, microsatellite instability; PIK3CA, phosphatidylinositol-4,5-biphosphonate 3-kinase; PTGS2, prostaglandin-
endoperoxide synthase 2.
aMultivariable model adjusted for age, gender, year of diagnosis, grade, MSI status, Eastern Cooperative Oncology Group performance status, family history of
colorectal cancer, adjuvant chemotherapy use and stage.
bMultivariable model adjusted for all variables in footnote (a), and also adjusted for Charlson comorbidity score.
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non-users in PTGS2-high tumors (adjusted HR= 0.55, 95%CI
0.32–0.96), whereas no improvement was observed in
PTGS2-low tumors (adjusted HR= 1.19, 95% CI 0.68–2.07,
P for interaction 0.09, Table 3). Similar results were observed
for overall survival with evidence of a significant interaction
(PTGS2-high adjusted HR=0.64, 95% CI 0.42–0.98 vs.
PTGS2-low adjusted HR=1.28, 95% CI 0.80–2.03, P for
interaction= 0.04, Table 3).
Sensitivity/subgroup analyses. The associations described
above were not markedly altered when statin use at the time
of diagnosis was included in the multivariable model (Table 4),
or when PIK3CA mutations were limited to exons 9 and 20
(see Supplementary Table S3). However, the association
between improved cancer-specific survival and aspirin use in
PTGS2-high tumors was more pronounced when the PTGS2
H-score cutoff point was increased. This association was
attenuated when the cutoff point was decreased (see
Supplementary Table S4).
DISCUSSION
Exposure to aspirin was associated with improved
survival in this population-based cohort study of stage II
and III colon cancer patients. In stratified analyses there
was no evidence of an interaction between aspirin use and
tumor PIK3CA mutation status. However, the asso-
ciation between aspirin use and improved survival was
more pronounced in tumors with higher levels of PTGS2
expression.
Previous studies investigating the association between
these biomarkers (PTGS2 and PIK3CA), aspirin use and
survival in colorectal cancer have reported mixed results.
Using data from two US cohort studies, Chan et al.9
demonstrated that aspirin use after colorectal cancer
diagnosis was associated with marked survival benefits
in tumors that overexpressed PTGS2 compared to those
that did not. Reimers et al.14 were unable to replicate this
finding in a large Dutch population-based cohort study.
Similarly, Domingo et al.7 did not observe a differential survival
effect for aspirin use according to PTGS2 status following
molecular analysis of the cohort of patients enrolled in the
VICTOR trial.
The first notable difference between these studies is that
Chan et al.9 considered both high- and low-dose aspirin users
whereas the other studies were limited to low-dose aspirin
only. The proportion of PTGS2-positive tumors in these
cohorts also varied considerably (68.4%9 vs. 56.3%14 vs.
21.0%7 respectively). In addition to the choice of primary
antibody, differences in the definition of PTGS2 overexpres-
sion were also present. In particular, while all studies have
assessed the intensity of PTGS2 immunostaining using the
methods described by Chan et al.9 only tumors with the
strongest staining intensity were considered overexpressors
by Domingo et al.7 Subsequently there was a marked
discrepancy between the proportions of PTGS2-positive
tumors (21.0 vs. 68.4%) in the VICTOR trial7 cohort and the
seminal US cohorts.9
The current population-based cohort study is the first
to corroborate the findings described by Chan et al.9Ta
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regarding an interaction between aspirin exposure, PTGS2
overexpression and better survival in colorectal cancer.
Similar to the Dutch14 and VICTOR trial7 cohorts, the current
study is representative of low-dose aspirin exposure only.
Importantly though, 64.1% of tumors were defined as having
higher levels of PTGS2 expression in our study, which more
closely matches the proportions observed using the methods
described by Chan et al.9 This association also became more
pronounced in sensitivity analyses that increased the PTGS2
H-score threshold, which increases the robustness and
biological plausibility of this finding.
Given the problems associated with standardizing
immunohistochemical techniques across pathology
laboratories, mutated PIK3CA has been proposed as a
more reliable biomarker to identify colorectal tumors sensitive
to aspirin.6 Liao et al.6 were the first to report that the pre-
sence of PIK3CA mutations differentiated the improved
survival benefit observed with aspirin use in colorectal
cancer. This finding was subsequently validated using
data from the VICTOR trial cohort.7 Similar to the findings in
the Dutch colorectal cancer cohort14 however, we did not
observe evidence of an interaction between low-dose
aspirin use and the presence of PIK3CA mutations. Aspirin
use at the time of diagnosis was also not associated with a
significant improvement in colorectal cancer-specific survival
in a retrospective cohort of 185 patients with mutant PIK3CA
tumors.13 However, stage IV tumors were included in that
cohort and there was no comparative group to assess for an
interaction.
Two meta-analyses have assessed the interaction
between aspirin use after diagnosis and PIK3CA mutation in
observational studies of colorectal cancer patients.23,24
Paleari et al.23 found that aspirin use in patients with PIK3CA
mutated tumors was associated with a 29% significant
reduction in overall mortality.23 In the meta-regression
analysis, however, there was no evidence of a significant
interaction between PIK3CA mutation status and aspirin
efficacy (P= 0.40) for overall survival. The authors of this
review did, however, recognize the potential for immortal time
bias in two of the included studies assessing overall
survival,6,7 where follow-up commenced at the time of color-
ectal cancer diagnosis but exposure to aspirin treatment
started at a non-specified time during subsequent follow-
up.23,25 In the present study aspirin use was assessed early in
the post-operative period therefore the risk of immortal time
bias is minimized.
A more recent meta-analysis by Elwood et al.24
has also noted a marked protective association for aspirin
and colorectal cancer-specific survival in PIK3CA-mutant
tumors. However, the magnitude of their risk estimate
(HR=0.45, 95% CI 0.28–0.71) may be exaggerated due to
the inclusion of an estimate for recurrence-free survival
from one study that did not report cancer-specific survival7
and erroneous inclusion of an estimate relating to PTGS2-high
tumors, rather than PIK3CA-mutant tumors, from another
study.9
Although there appears to be evidence for a benefit from
previous work,6,7 accurately determining the magnitude of a
differential association by PIK3CA status has implications for
clinical trial design. The failure to demonstrate a significant
interaction in both the meta-regression of previous observa-
tional studies23 and the present cohort would suggest that
caution is required before considering additional randomized
clinical trials that only recruit patients with mutated PIK3CA
tumors (NCT02647099 and NCT02467582). On this basis,
planned PTGS2 and PIK3CA subgroup analysis of trials
evaluating adjuvant aspirin use in colorectal cancer patients,
irrespective of tumor molecular profile, is perhaps more
appropriate.
A major strength of this study is the inclusion of
population-representative colon cancer patients. Further-
more, application of a precise, automated and validated
digital immunoscoring system ensures reproducible immuno-
expression data. However, there are a number of limitations
that warrant further discussion. Most importantly, information
on aspirin prescription was only assessed in the early
post-operative period and no information was available
regarding the duration of previous exposure. Assessment at
this single time point may not reflect changes in post-
diagnostic use and could lead to misclassification bias.23,25
However, the optimal duration and timing of aspirin
exposure is not clear from observational data to date. It is
possible that the important intervention period for aspirin
use is in the early post-operative period, as seen for
chemotherapy,26,27 in which case our data would capture the
optimal aspirin time point. Over the counter medication use is
another source of bias in pharmacoepidemiology studies,
however medication records in COIS and the medical charts
relied on a doctor patient interaction, therefore significant over
the counter use is likely to have been captured. Also, previous
pharmacoepidemiology studies have confirmed that between
75 and 98% of chronic low-dose aspirin use in the age-group
of patients included in this cohort in the UK was by
prescription.28,29
The ColoCarta panel also only identifies 79% of known
PIK3CA mutations. However, these hotspot mutations are
representative of 84%of the exon 9 and 20mutations detected
in the seminal paper by Liao et al.6 It is therefore unlikely that
detection of less common mutations would alter the PIK3CA
stratified results as the number of additional aspirin users
assigned as having a PIK3CA-mutant tumor would be small.
Finally, we were unable to adjust for a number of confounding
factors such as physical inactivity and obesity.30–32 However,
to the best of the authors’ knowledge, there is no evidence to
suggest these factors would impact analyses stratified by
PTGS2 or PIK3CA status.
Caution should be exercised when considering the associa-
tion between better survival and aspirin use in the PTGS2-high
subgroup given the borderline significance and multiple
hypotheses tested. However, in sensitivity analyses the
relationship appeared to be independent of statin use, a
further medication with potential anti-cancer effects,33 and
became more significant when the threshold PTGS2 H-score
cutpoint was increased. Statistical power to detect an
interaction by PIK3CA mutation status was also limited.
However, the numbers were similar to the study by Domingo
et al.7 who only had 14 aspirin users in the PIK3CA-mutant
group; the only difference being they had no events in this
group whereas five events were observed among 17 patients
in our cohort.
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In summary, aspirin use was associated with better
survival in this population-based colon cancer cohort study
and the association was more pronounced in tumors with
higher levels of PTGS2 expression. In contrast, no sig-
nificant interaction was observed with PIK3CA mutation
status therefore caution should be exercised when con-
sidering trials assessing aspirin use in PIK3CA mutated
tumors only. Planned subgroup analysis of trials evaluating
adjuvant aspirin therapy in colorectal cancer patients,
irrespective of tumor molecular profile, may therefore be more
appropriate.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Epidemiological studies suggest aspirin use may be
associated with improved survival after colorectal cancer
diagnosis.
✓ This association may vary according to molecular markers
of phosphatidylinositol 3-kinase (PI3K) signaling activity.
WHAT IS NEW HERE
✓ Aspirin use was associated with improved colorectal
cancer-specific survival.
✓ The association with mortality differed according to PTGS2
expression but not PIK3CA mutation status.
TRANSLATIONAL IMPACT
✓ Limiting adjuvant aspirin trials to PIK3CA-mutant colorectal
cancer may be too restrictive.
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